)
Ranbaxy Malaysia Sdn Bhd, a joint venture between India's largest pharmaceutical company Ranbaxy Laboratories Limited and Malaysian shareholders, has been allocated the site for setting up its greenfield manufacturing facility in Malaysia.
The company has signed a letter of offer agreement with Kulim Hi Tech Park (KHTP), a fully-owned state agency and industrial park. KHTP is located at Kulim in Kedah state of Malaysia. The local government has given its approval to Ranbaxy Malaysia for setting up the facility as an entry point project (EPP).
In a filing to the BSE on Thursday, Ranbaxy said that the greenfield facility, which will be its second manufacturing plant in Malaysia, will be built on 15-acre with an investment of $35 million, providing employment to over 200.
The proposed facility would manufacture dosage forms, including tablets and capsules, primarily in the cardiovascular, anti-diabetic, anti-infective and gastrointestinal segments. Once the new plant is fully operational, Ranbaxy’s total output in Malaysia will be increased from one billion doses a year to three billion doses a year, the company said in the filing.
